Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novo no show for Tresiba in Germany

This article was originally published in Scrip

Executive Summary

It's too big a risk for Novo Nordisk to launch its diabetes drug Tresiba (insulin degludec) in Germany thanks to the AMNOG pricing and reimbursement system, said the firm's vice president of marketing and medical affairs, Jacob Riis. Novo Nordisk believes that it would have to sacrifice too much on price. "Even though we have the documentation, both clinically and from a health economics point of view, we are not convinced the German authorities will acknowledge the benefits of Tresiba, " said Mr Riis.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts